Chemistry:EB-002

From HandWiki

EB-002, also formerly known as EB-373, is a synthetic prodrug of the non-selective serotonin receptor agonist and serotonergic psychedelic psilocin which is under development for the treatment of neuropsychiatric disorders like depression and anxiety disorders.[1][2][3][4][5] It is taken orally.[1] The drug is under development by Enveric Biosciences.[1][2][3][5] As of November 2024, it is in the preclinical research stage of development.[1][2] In November 2024, Enveric Biosciences out-licensed EB-002 to MycoMedica Life Sciences in a deal that was estimated to be worth as much as $62 million.[3] Its exact chemical structure does not yet appear to have been disclosed.[1]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 "Enveric Biosciences". 22 November 2024. https://adisinsight.springer.com/drugs/800070554. 
  2. ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on EB-373 with Synapse". 25 January 2025. https://synapse.patsnap.com/drug/d32cadac7ad14863850498acfa540d28. 
  3. ↑ 3.0 3.1 3.2 "Enveric inks $62M licensing deal for psilocin prodrug". 12 November 2024. https://www.greenmarketreport.com/enveric-inks-62m-licensing-deal-for-psilocin-prodrug/. 
  4. ↑ "Investigational Psilocin Prodrug Gains Patent Protection for Sleep Disorder Applications". 18 July 2024. https://sleepreviewmag.com/sleep-treatments/pharmaceuticals/emerging-compounds/investigational-psilocin-prodrug-gains-patent-protection-sleep-disorder-applications/. 
  5. ↑ 5.0 5.1 Carreon, Mary (30 July 2024). "Another Psychedelic Drug Derivative Secures Patent and Awaits FDA Approval". https://doubleblindmag.com/patents-and-trip-free-psychedelics/. 

Template:Psychedelics



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:EB-002&oldid=4029198"